Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?
BioDrugs · 2024-03 · 38 (2) · 171-176
DOI: 10.1007/s40259-024-00643-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioDrugs, online erschienen am 18.01.2024. Verfasst von Daniel V Santi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Prolynx, Inc., 135 Mississippi Street, San Francisco, CA, 94107, USA. Daniel.V.Santi@Prolynxinc.com. Hauptthemen laut MEDLINE: Prodrugs, Neoplasms, Immunoconjugates, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
We previously proposed that sacituzumab govitecan (SG, Trodelvy®) likely acts as a simple prodrug of systemic SN-38 as well as an antibody drug conjugate (ADC). In the present commentary, we assess whether a long-acting SN-38 prodrug, such as PLX038, might be efficacious in SG-resistant patients. We first describe possible mechanisms of action of SG, with new insights on pharmacokinetics and TROP2 receptor occupancy. We argue that SG is not an optimal conventional ADC and that the amount of systemic SN-38 spontaneously hydrolyzed from the ADC is so high it must have activity. Then, we describe the concept of time-over-target as related to the pharmacology of SG and PLX038 as SN-38 prodrugs. To be clear, we are not in any way suggesting that PLX038 or any SN-38 prodrug is superior to SG as an anticancer agent. Clearly, SG has the benefit over antigen-independent SN-38 prodrugs in that it targets cells with the TROP2 receptor. However, we surmise that PLX038 should be a more efficacious and less toxic prodrug of systemic SN-38 than SG. Finally, we suggest possible mechanisms of SG resistance and how PLX038 might perform in the context of each. Taken together, we argue that-contrary to many opinions-SG does not exclusively act as a conventional ADC, and propose that PLX038 may be efficacious in some settings of SG-resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Prolynx, Inc., 135 Mississippi Street, San Francisco, CA, 94107, USA. Daniel.V.Santi@Prolynxinc.com.
- Pharmaceutical Chemistry, UCSF, San Francisco, CA, USA. Daniel.V.Santi@Prolynxinc.com.
- Prolynx, Inc., 135 Mississippi Street, San Francisco, CA, 94107, USA.
- Medical Oncology, Institut Curie, Paris, France.
- UVSQ/Paris Saclay University, Paris, France.
Zitieren
APA
Santi, D. V., Ashley, G. W., Cabel, L., & Bidard, F. C. (2024). Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?. BioDrugs, 38(2), 171-176. https://doi.org/10.1007/s40259-024-00643-8
Vancouver
Santi DV, Ashley GW, Cabel L, Bidard FC. Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?. BioDrugs. 2024;38(2):171-176. doi:10.1007/s40259-024-00643-8
BibTeX
@article{Santi2024,
author = {Santi, Daniel V and Ashley, Gary W and Cabel, Luc and Bidard, Francois-Clement},
title = {Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?},
journal = {BioDrugs},
year = {2024},
volume = {38},
number = {2},
pages = {171--176},
doi = {10.1007/s40259-024-00643-8}
}
EUVIMED